The lecture describes the role of T2 inflammation in the transition from recurrent wheezing to childhood asthma, asthma exacerbations and treatment response. The impact of early life exposures is discussed in depth. Several case studies guide de leaner for understanding personalized decisions in pediatric asthma.

The lecture discusses atopic dermatitis pathogenesis with a focus on the use of biomarkers to separate clinical phenotypes as a basis for the personalized approach. The value of skin profiling for cytokines, barrier function and microbiome as a basis of treatment decisions in the clinic is further discussed.

The lecture provides an in depth description of the allergen-specific and general type 2 immune response with tissue and blood eosinophilia, excessive and bad mucus production, tissue remodeling, barrier disfunction, microbial dysbiosis, the role of key cytokines (IL4, IL13, IL5, IL9, TSLP, IL33, IL25). The origins of the T2 response are also discussed, together with the environmental impact. At the end practical examples on how to measure barrier dysfunction are described.

The lecture provides an overview of T2 asthma, from pathogenesis and biomarkers to clinical characteristics and co-morbidities. The inflammatory circuitry in T2 asthma involving allergy, epithelial dysfunction and T2 immune response and its modulation by viral infections and pollutants is discussed in depth. Three patient cases guide the learner in understanding how to personalize treatment of T2 asthma in the clinic.

The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions.

The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions.

The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis.

The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis.

The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma.

The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma.

Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

This is a non-promotional, non-CME disease state educational webcast brought to you by EAACI in collaboration with and paid for by GlaxoSmithKline

An in-depth, interactive e-learning resource aimed at improving the diagnosis and management of T2 diseases as long-term conditions for children and adults. This first educational module focuses on the T2 complex endotype and aims to define and understand the pathogenesis of T2 immune-inflammatory response, its biomarkers and visible properties, adapted to specialized care (specialists in allergy and clinical immunology, pneumology, ENT, dermatology, paediatrics).

The lecture provides an overview of T2 asthma, from pathogenesis and biomarkers to clinical characteristics and co-morbidities. The inflammatory circuitry in T2 asthma involving allergy, epithelial dysfunction and T2 immune response and its modulation by viral infections and pollutants is discussed in depth. Three patient cases guide the learner in understanding how to personalize treatment of T2 asthma in the clinic.

The lecture provides an overview of T2 asthma, from pathogenesis and biomarkers to clinical characteristics and co-morbidities. The inflammatory circuitry in T2 asthma involving allergy, epithelial dysfunction and T2 immune response and its modulation by viral infections and pollutants is discussed in depth. Three patient cases guide the learner in understanding how to personalize treatment of T2 asthma in the clinic.

The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions.

The lecture describes the role of T2 inflammation in the transition from recurrent wheezing to childhood asthma, asthma exacerbations and treatment response. The impact of early life exposures is discussed in depth. Several case studies guide de leaner for understanding personalized decisions in pediatric asthma.

The lecture describes the role of T2 inflammation in the transition from recurrent wheezing to childhood asthma, asthma exacerbations and treatment response. The impact of early life exposures is discussed in depth. Several case studies guide de leaner for understanding personalized decisions in pediatric asthma.

The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis.

The lecture discusses atopic dermatitis pathogenesis with a focus on the use of biomarkers to separate clinical phenotypes as a basis for the personalized approach. The value of skin profiling for cytokines, barrier function and microbiome as a basis of treatment decisions in the clinic is further discussed. Clinical cases facilitate the understanding clinical phenotyping in atopic dermatitis. Another atopic co-morbidity, alopecia areata, is also presented as an example of T2 driven inflammation in the skin. The combination between T2 and T17 and T1 immune response as a basis of chronicity is explained with examples from targeted interventions in clinical trials and in the clinic.

The lecture discusses atopic dermatitis pathogenesis with a focus on the use of biomarkers to separate clinical phenotypes as a basis for the personalized approach. The value of skin profiling for cytokines, barrier function and microbiome as a basis of treatment decisions in the clinic is further discussed. Clinical cases facilitate the understanding clinical phenotyping in atopic dermatitis. Another atopic co-morbidity, alopecia areata, is also presented as an example of T2 driven inflammation in the skin. The combination between T2 and T17 and T1 immune response as a basis of chronicity is explained with examples from targeted interventions in clinical trials and in the clinic.

The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma.

The lecture provides an in depth description of the allergen-specific and general type 2 immune response with tissue and blood eosinophilia, excessive and bad mucus production, tissue remodeling, barrier disfunction, microbial dysbiosis, the role of key cytokines (IL4, IL13, IL5, IL9, TSLP, IL33, IL25). The origins of the T2 response are also discussed, together with the environmental impact. At the end practical examples on how to measure barrier dysfunction are described.

The lecture provides an in depth description of the allergen-specific and general type 2 immune response with tissue and blood eosinophilia, excessive and bad mucus production, tissue remodeling, barrier disfunction, microbial dysbiosis, the role of key cytokines (IL4, IL13, IL5, IL9, TSLP, IL33, IL25). The origins of the T2 response are also discussed, together with the environmental impact. At the end practical examples on how to measure barrier dysfunction are described.

Food allergy can result in considerable morbidity, impact negatively on quality of life, and prove costly in terms of medical care. It is mostly IgE-mediated and a chronic disease affecting up to 4% of the European population.

Food allergy can result in considerable morbidity, impact negatively on quality of life, and prove costly in terms of medical care. It is mostly IgE-mediated and a chronic disease affecting up to 4% of the European population.

Food allergy can result in considerable morbidity, impact negatively on quality of life, and prove costly in terms of medical care. It is mostly IgE-mediated and a chronic disease affecting up to 4% of the European population.

Food allergy can result in considerable morbidity, impact negatively on quality of life, and prove costly in terms of medical care. It is mostly IgE-mediated and a chronic disease affecting up to 4% of the European population.